• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Latest News

Featured News

Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma

Aug 19, 2026

Select the category

  • All categories
  • Covid-19
  • GlyMab
  • Immunobody
  • Interviews
  • iSCIB1+
  • Latest News
  • Media Coverage
  • Modi-1
  • Modi-2
  • Moditope
  • News
  • Presentations
  • Regulatory News
  • SCIB1

Select the year

  • All years
  • 2022
  • 2023
  • 2024
  • 2025
  • 2026
Clear Filters
U

Director Dealing

September 16, 2025

Preliminary Results for the Year Ended 30 April 2025

September 11, 2025

Notice of Results

September 4, 2025

Director Dealing

August 8, 2025

Director Dealing

August 4, 2025

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

July 22, 2025
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 5
No results found.

Regulatory News Archive

View archive

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy